Cerity Partners
ALLO icon

Cerity Partners’s Allogene Therapeutics ALLO Stock Holding History

Cerity Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$687K Buy
330,290
+173,055
+110% +$380K ﹤0.01% 2232
2026
Q1 		$384K Buy
157,235
+59,326
+61% +$119K ﹤0.01% 2446
2025
Q4 		$134K Sell
97,909
-368,823
-79% -$487K ﹤0.01% 2710
2025
Q3 		$579K Buy
466,732
+66,465
+17% +$79.2K ﹤0.01% 1881
2025
Q2 		$452K Buy
400,267
+19,843
+5% +$26.4K ﹤0.01% 1917
2025
Q1 		$555K Sell
380,424
-6,963
-2% -$13.1K ﹤0.01% 1703
2024
Q4 		$832K Sell
387,387
-44,995
-10% -$111K ﹤0.01% 1506
2024
Q3 		$1.21M Buy
432,382
+232
+0.1% +$618 ﹤0.01% 1314
2024
Q2 		$1.01M Buy
432,150
+7,981
+2% +$23.5K ﹤0.01% 1224
2024
Q1 		$1.9M Sell
424,169
-93,412
-18% -$390K 0.01% 994
2023
Q4 		$1.66M Buy
+517,581
New +$1.47M 0.01% 819
2023
Q3 		– Sell
-598,100
Closed -$2.97M – 1400
2023
Q2 		$2.97M Sell
598,100
-1,954
-0.3% -$10.6K 0.01% 625
2023
Q1 		$2.96M Buy
600,054
+10,800
+2% +$69.3K 0.01% 603
2022
Q4 		$3.71M Sell
589,254
-41,171
-7% -$381K 0.02% 413
2022
Q3 		$6.81M Buy
630,425
+29,411
+5% +$400K 0.08% 202
2022
Q2 		$6.85M Sell
601,014
-100,039
-14% -$888K 0.08% 214
2022
Q1 		$6.39M Sell
701,053
-2,333
-0.3% -$24.3K 0.1% 169
2021
Q4 		$10.5M Buy
703,386
+305,334
+77% +$5.39M 0.16% 119
2021
Q3 		$10.2M Sell
398,052
-2,100
-0.5% -$49.9K 0.23% 96
2021
Q2 		$10.4M Sell
400,152
-1,450
-0.4% -$41.4K 0.23% 89
2021
Q1 		$14.2M Buy
+401,602
New +$13.5M 0.34% 63

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cerity Partners's ALLO Position: Q2 2026 in Review

Cerity Partners increased its Allogene Therapeutics (ALLO) stake by 110% in Q2 2026, buying an estimated $380K and bringing the position to 330,290 shares worth $687K. The position accounts for ﹤0.01% of the portfolio, ranked #2232.

Cerity Partners first reported a position in ALLO in Q1 2021 and has held it in 21 quarters since. The position peaked at $14.2M in Q1 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Cerity Partners held 330,290 shares of Allogene Therapeutics worth $687K as of Q2 2026.
  • Cerity Partners bought 173,055 Allogene Therapeutics shares in Q2 2026, an estimated $380K.
  • Allogene Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2232 holding.
  • Cerity Partners first reported a position in Allogene Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Cerity Partners's Allogene Therapeutics position peaked at $14.2M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.